FHTX trades 184.4% below Wall Street's consensus target of $12.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FHTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Foghorn Therapeutics Inc. (FHTX) has a Wall Street consensus price target of $12.00, based on estimates from 9 covering analysts. With the stock currently trading at $4.22, this represents a potential upside of +184.4%. The company has a market capitalization of $248M.
Analyst price targets range from a low of $12.00 to a high of $12.00, representing a 0% spread in expectations. The median target of $12.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, FHTX trades at a trailing P/E of -3.6x. Analysts expect EPS to grow +5.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
RVMDRevolution Medicines, Inc. | $38.7B | $182.08 | $165.75 | -9.0% | Buy | — | 22 |
TNGXTango Therapeutics, Inc. | $3.7B | $31.47 | $46.00 | +46.2% | Buy | — | 13 |
VYNEVYNE Therapeutics Inc. | $28M | $0.66 | — | — | — | — | — |
PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
AUPHAurinia Pharmaceuticals Inc. | $2.2B | $17.23 | $12.60 | -26.9% | Buy | 17.9x | 15 |
KYMRKymera Therapeutics, Inc. | $8.8B | $108.12 | $123.50 | +14.2% | Buy | — | 26 |
ARQTArcutis Biotherapeutics, Inc. | $3.4B | $27.00 | $34.00 | +25.9% | Buy | 135.6x | 12 |
IMVTImmunovant, Inc. | $8.0B | $38.85 | $45.00 | +15.8% | Buy | — | 23 |
PMVPPMV Pharmaceuticals, Inc. | $62M | $1.17 | — | — | — | — | — |
STROSutro Biopharma, Inc. | $295M | $30.52 | $51.50 | +68.7% | Buy | — | 20 |
Quick answers to the most common questions about buying FHTX stock.
The consensus Wall Street price target for FHTX is $12, representing 184.4% upside from the current price of $4.22. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
FHTX has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 184.4% upside from current levels.
FHTX's current price is $4.22 with a consensus target of $12 (184.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for FHTX, while the most conservative target is $12. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
FHTX is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FHTX stock forecast based on 9 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $12 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on FHTX, with a "Buy" consensus rating and $12 price target (184.4% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FHTX analyst price targets range from $12 to $12, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.